Exact Sciences reported third-quarter results that fell short of ... a “shocking guidance update,” contributed to a 23% drop ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...

Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...

QRG Capital Management Inc. grew its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 13.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The ...

On Wednesday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $54.72 which represents a decrease of $-16.79 or -23.48% from the prior close of $71.51. The stock opened at $55.7 and ...

On Wednesday, Benchmark analyst Bruce Jackson revised the price target on shares of Exact Sciences (NASDAQ:EXAS), reducing it to $65 from the previous $67, while reiterating a Buy rating on the stock.

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday. Shares of Exact ...